This site provides INTERCEPT product information for Health Care Professionals in the United States. View other Cerus websites

  • About Cerus
  • Events
  • What is Pathogen Reduction?
      • Back
      • INTERCEPT Pathogen Reduced Platelets
      • INTERCEPT Pathogen Reduced Plasma
      • Safety, Efficacy and Hemovigilance
      • Inactivation Data
  • Why INTERCEPT?
      • Back
      • The Need for Platelet Safety
      • Infectious Risk
      • Healthcare Acquired Infections
      • Was it the Platelets?
      • Recognizing a Septic Transfusion Reaction
      • Sepsis and Surveillance
      • T-Cells and TA-GVHD
      • Impact on Patients : Case Study
  • Getting Started
      • Back
      • Implementing INTERCEPT in the Hospital Setting
      • Blood Center Partners
  • Resources
      • Back
      • Package Inserts
      • Product Information
      • Case Studies
      • Publications
      • Implementation Tools
      • Standards & Policies
          • Back
          • FDA Federal Register
          • AABB Standards and TA-GVHD Prevention
          • FDA Guidance on Zika
          • FDA Guidance on Babesia
          • FDA Final Guidance
      • All Resources
      • Free CE Modules
      • Coding and Billing Guide
      • Webinars & Podcasts
  • Contact Us
      • Back
      • Contact Us
      • Educational Support
  • About Cerus
  • Events
  • Forgot your password?
  • Forgot your username?
cerus

Sitemap | Legal Info | Cookies Policy and Tracking Opt-Out Guide  | Privacy Policy | United States  

Rx Only. For CONTRAINDICATIONS and WARNINGS, click here. See package insert for full prescribing information – available on the resource page. There is no pathogen inactivation process that has been shown to eliminate all pathogens. ©2021 Cerus Corporation. All Rights Reserved. INTERCEPT, INTERCEPT Blood System and CERUS are registered trademarks of Cerus Corporation. This site is intended for US audiences only. MKT-EN 00401 v2.0